These findings greatly expand our understanding of LXN as a tumor suppressor and highlight the potential role of LXN in tumor immunomodulation by regulating the polarization of macrophage as well as the expression of immune checkpoint molecule PD-L2, which we believe has practical significance in the clinical treatment of immune-checkpoint of tumor patients. This evidence concerns the gene PDCD1LG2 and neoplasm.